Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis

Journal of Nephrology

Volumn 28, Issue 3, 2015, Pages 299-305

  Musetti, Claudio ^a   Quaglia, Marco ^a   Cena, Tiziana ^b   Chiocchetti, Annalisa ^b   Monti, Sara ^a   Clemente, Nausicaa ^b   Magnani, Corrado ^b   Dianzani, Umberto ^b   Stratta, Piero ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Autoimmunity; Glomerular filtration rate; Primary glomerulonephritis; Proteinuria; Secondary glomerulonephritis; suPAR

Indexed keywords

UROKINASE RECEPTOR; BIOLOGICAL MARKER; PLAUR PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIMARY GLOMERULONEPHRITIS; PROTEINURIA; SECONDARY GLOMERULONEPHRITIS; AGED; AUTOIMMUNITY; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOLOGY; ITALY; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR; STATISTICAL MODEL; UPREGULATION;

ADULT; AGED; AUTOIMMUNITY; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; ITALY; KIDNEY; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROTEINURIA; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK FACTORS; UP-REGULATION;

EID: 84924124739     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0137-1     Document Type: Article

References (23)

1. Thunø M, Macho B, Eugen-Olsen J (2009) suPAR: the molecular crystal ball. Dis Markers 27(3):157–172
2. Montuori N, Ragno P (2009) Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci (Landmark Ed) 14:2494–2503
3. Backes Y, van der Sluijs KF, Mackie DP et al (2012) Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38(9):1418–1428
4. Persson M, Ostling G, Smith G et al (2014) Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke 45(1):18–23
5. Sehestedt T, Lyngbæk S, Eugen-Olsen J et al (2011) Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 216(1):237–243
6. Enocsson H, Wettero J, Skogh T et al (2013) Soluble urokinase-like receptor activator levels reflect organ damage in systemic lupus erythematosus. Transl Res 162(5):287–296
7. Trimarchi H (2013) Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. World J Nephrol 2(4):103–110
8. Wei C, El Hindi S, Li J et al (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17(8):952–960
9. Wei C, Trachtman H, Li J et al (2012) Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23(12):2051–2059
10. Alachkar N, Wei C, Arend LJ et al (2013) Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 96(7):649–656
11. Morath C, Wei C, Macher-Goeppinger S et al (2013) Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification. Am J Ther 20(2):226–229
12. Jefferson JA, Shankland SJ (2013) Has the circulating permeability factor in primary FSGS been found? Kidney Int 84(2):235–238
13. Welsh GI, Saleem MA (2011) The podocyte cytoskeleton–key to a functioning glomerulus in health and disease. Nat Rev Nephrol 8(1):14–21
14. Maas RJ, Deegens JK, Wetzels JF (2013) Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 28(7):1041–1048
15. Naesens M, Meijers B, Sprangers B (2013) suPAR and FSGS: the gap between bench and bedside. Transplantation 96(4):368–369
16. Meijers B, Maas RJ, Sprangers B et al (2014) The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85(3):636–640
17. Huang J, Liu G, Zhang YM et al (2013) Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84(2):366–372
18. Wada T, Nangaku M, Maruyama S et al (2014) A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int 85(3):641–648
19. Sinha A, Baipal J, Saini S et al (2014) Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85(3):649–658
20. Segarra A, Jatem E, Quiles MT et al (2014) Diagnostic value of soluble urokinase-type plasminogen activator receptor levels in adults with idiopathic nephrotic syndrome. Nefrologia 34(1):46–52
21. Segarra A, Segarra A, Jatem E et al (2014) Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis. Nefrologia 34(1):53–61
22. Franco Palacios CR, Lieske JC, Wadei HM et al (2013) Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96(4):394–399
23. Outinen TK, Mäkelä S, Huttunen R, et al. (2014) Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection. J Intern Med. doi:10.1111/joim.12257 (Epub ahead of print)